Research Index
Retatrutide Research Index
PSI surfaces 50 peer-reviewed studies on Retatrutide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
GIPR:GCGR co-agonism restores normal weight in obese rodents.
Perez-Tilve D, Zhang F, Zhang Y et al.
Mol Metab·2026·Animal·PubMed →
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
Li Q, Cheng W, Zhang J et al.
Diabetol Metab Syndr·2026·Animal·PubMed →
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
Briand F, Le Cudennec C, Grasset E et al.
Obesity (Silver Spring)·2026·Animal·PubMed →
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
Hitaka K, Sugawara T, Matsumoto M et al.
Int J Obes (Lond)·2026·Animal·Weight Loss·PubMed →
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Chan ZH, Omar AS, Gill K et al.
Cardiol Rev·2026·Animal·PubMed →
Development of the Weight and Emotions Scale (WES).
Kanu C, Kimel M, Goetz I et al.
Obes Sci Pract·2026·Animal·PubMed →
[Nephrology : what's new in 2025].
Nanchen G, Pruijm M, Lamine F et al.
Rev Med Suisse·2026·Animal·Glycemic Control·PubMed →
Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.
Kanu C, Clucas C, Skalicky A et al.
Adv Ther·2026·Animal·Weight Loss, Appetite Regulation·PubMed →
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, Kaplan LM, Somers VK et al.
Diabetes Obes Metab·2026·Animal·Osteoarthritis, Sleep Apnea, Weight Loss·PubMed →
Inotropic effects of retatrutide in isolated human atrial preparations.
Neumann J, Ahlrep U, Hofmann B et al.
Naunyn Schmiedebergs Arch Pharmacol·2026·Animal·PubMed →
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Goetz IA, Kanu C, Hoover A et al.
Obes Pillars·2025·Human·PubMed →
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease.
Heerspink HJL, van Raalte DH, Bjornstad P et al.
Nephrol Dial Transplant·2025·Human·PubMed →
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Kanu C, Boye KS, Poon JL et al.
Diabetes Obes Metab·2025·Human·Glycemic Control, Appetite Regulation, Weight Loss·PubMed →
Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.
Kanu C, Wu Q, Poon JL et al.
Diabetes Obes Metab·2025·Human·PubMed →
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
Wen Y, Lemen D, Lin Y et al.
Diabetes Obes Metab·2025·Human·Glycemic Control·PubMed →
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
Heerspink HJL, Lu Z, Du Y et al.
Kidney Int Rep·2025·Human·PubMed →
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC et al.
Lancet Diabetes Endocrinol·2025·Human·Glycemic Control·PubMed →
Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
Guo H, Yang J, Huang J et al.
Obes Pillars·2025·Human·PubMed →
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.
Viebahn GK, Khurana A, Freund L et al.
Am J Physiol Gastrointest Liver Physiol·2025·Animal·Liver Protection, Liver Fat (MASLD)·PubMed →
Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.
Wang S, Liu Y, Yan Z et al.
J Med Chem·2025·Animal·Weight Loss, Glycemic Control·PubMed →
Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.
Basile C, Merolla A, Mancusi C et al.
Eur J Prev Cardiol·2025·Animal·PubMed →
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
Windram M, Lovelock DF, Carew JM et al.
Psychopharmacology (Berl)·2025·Animal·PubMed →
Contractile effects of retatrutide in isolated mouse atrial preparations.
Neumann J, Ahlrep U, Hofmann B et al.
Naunyn Schmiedebergs Arch Pharmacol·2025·Animal·PubMed →
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
Marathe SJ, Grey EW, Bohm MS et al.
NPJ Metab Health Dis·2025·Animal·PubMed →
Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
Cui X, Zhu Y, Zeng L et al.
Adv Sci (Weinh)·2025·Animal·Weight Loss·PubMed →
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
DiStefano MJ, Dardouri M, Moore GD et al.
J Pharm Policy Pract·2025·Animal·PubMed →
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
Ma J, Hu X, Zhang W et al.
Endocrine·2025·Animal·Glycemic Control·PubMed →
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Xie Z, Zheng G, Liang Z et al.
Metabolism·2024·Human·Weight Loss·PubMed →
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP et al.
Nat Med·2024·Human·Liver Fat (MASLD), Liver Protection, Weight Loss·PubMed →
The First Triple Agonist for Antiobesity: Retatrutide.
Tetelbaun L, Mullally JA, Frishman WH
Cardiol Rev·2024·Animal·PubMed →
The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
Deravi M, Piszczatoski C, Phillips B et al.
J Pharm Technol·2024·Animal·PubMed →
Retatrutide.
Ramsbacher N
Clin Diabetes·2024·Animal·PubMed →
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.
Li W, Zhou Q, Cong Z et al.
Cell Discov·2024·Animal·PubMed →
Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.
Naeem M, Imran L, Banatwala UESS
Health Sci Rep·2024·Animal·PubMed →
Recent advances in peptide-based therapies for obesity and type 2 diabetes.
Bailey CJ, Flatt PR, Conlon JM
Peptides·2024·Animal·Glycemic Control, Weight Loss·PubMed →
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
Ruder K
JAMA·2024·Animal·Glycemic Control, Weight Loss·PubMed →
Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
Seetharaman R, Pandit S
J Basic Clin Physiol Pharmacol·2024·Animal·Glycemic Control·PubMed →
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.
Tsilingiris D, Kokkinos A
Metabolism·2024·Animal·Glycemic Control, Weight Loss, Liver Fat (MASLD)·PubMed →
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM et al.
Lancet·2023·Human·PubMed →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP et al.
N Engl J Med·2023·Human·PubMed →
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
Polyzos SA, Frühbeck G, Kiortsis DN
Curr Pharm Des·2023·Animal·Liver Fat (MASLD), Glycemic Control·PubMed →
Retatrutide: a triple incretin receptor agonist for obesity management.
Ray A
Expert Opin Investig Drugs·2023·Animal·Glycemic Control, Weight Loss·PubMed →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
Jastreboff AM, Kaplan LM, Hartman ML
N Engl J Med·2023·Animal·Weight Loss·PubMed →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
Elfeki MA, Alkhouri N
N Engl J Med·2023·Animal·PubMed →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
Bisson A, Fauchier G, Fauchier L
N Engl J Med·2023·Animal·PubMed →
Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
Seetharaman R, Pandit S
J Basic Clin Physiol Pharmacol·2023·Animal·Weight Loss, Glycemic Control·PubMed →
Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
Harris E
JAMA·2023·Animal·Weight Loss·PubMed →
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
Bain SC, Min T
Lancet·2023·Animal·Glycemic Control·PubMed →
Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.
Sidik S
Nature·2023·Animal·Weight Loss·PubMed →
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
Urva S, O'Farrell L, Du Y et al.
Diabetes Obes Metab·2023·Animal·Glycemic Control·PubMed →